Jan Berger, MD, MJ

New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.

This article is the first in a 2-part series that summarizes the proceedings from a roundtable meeting that was conducted to discuss real-world considerations in nonvalvular atrial fibrillation and venous thromboembolism.

The authors describe and apply a methodology for defining tailored health communications in order to increase the number of completed colorectal cancer screenings.

During the first panel discussion at PCDC 2014, "Addressing Challenges in Diabetes," the panelists talked about individualizing patient care.

Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.

Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.